Breakthrough in the development of a diagnostic test for oesophageal cancer

February 8, 2012 in Cancer

Breakthrough in the development of a diagnostic test for oesophageal cancer

Enlarge

ALICE

A team of scientists, led by the University of Liverpool, has made a major advance in the development of a diagnostic test for oesophageal cancer. The findings, achieved at STFC's ALICE accelerator facility, will lead to major improvements in the diagnosis, treatment and prognosis of the disease.

Oesophageal cancer is the ninth most common cancer in the world and around 8000 people are diagnosed every year in the UK. It is an extremely difficult cancer to diagnose and is highly aggressive. Patients often present when the is at an advanced stage, when surgical removal is no longer possible.

The aim of the research is to develop a by imaging tissue obtained by from patients with a precursor condition called Barrett's Oesophagus. Patients with Barrett's Oesophagus are more at risk of developing this form of cancer and are regularly monitored to detect changes in their condition. If are detected in these patients, they can undergo potentially without the need for because the tumours have been detected at a much earlier stage.

By using a unique and extremely intense source of (the InfraRed ) at the pioneering ALICE accelerator at STFC's Daresbury Laboratory, Professor Peter Weightman and his team have been able to image and carry out a blind study of historical endoscopic samples from patients with Barrett's Oesophagus and, by detecting changes that took place in the samples, have developed a diagnostic test for the disease.

Minister for Universities and Science David Willetts said: “It’s incredibly impressive that the UK’s leading physics research can bring benefits for our health and wellbeing, as well as telling us more about the world around us. This work has the potential to save lives and revolutionise the diagnosis and treatment of oesophageal cancer. It also demonstrates the value of the Government’s investment in the Daresbury Laboratory. I wish the researchers well in taking these findings through to clinical use.”

Professor Weightman of University of Liverpool said: "Early diagnosis is the most important factor for improving the prognosis for patients with oesophageal cancer. But it is extremely hard to diagnose accurately - a false negative test can be fatal, whereas a false positive means unnecessary major surgery."

Project collaborator, Professor Mark Pritchard, Consultant Gastroenterologist at Royal Liverpool University Hospital said: "Unfortunately, many patients with have inoperable cancers by the time of presentation, and even when surgery is performed it can often be unsuccessful. There is a real, pressing clinical need to develop new technologies which can detect early changes that occur within individual cells prior to cancer development. Using ALICE, Professor Weightman has been able to detect such cellular changes. This technology may have similar applications in other types of cancer which have a well established premalignant stage."

Professor Weightman added: "Eventually we hope to develop a diagnostic test that can be used in an endoscope. The most promising approach may be to develop a test using the intense terahertz light also generated by ALICE. ALICE is Europe's most intense band source of terahertz light and the only one in the world equipped with a tissue culture facility for research on cancer. This would lead to much cheaper and more efficient diagnosis of the disease. However this development is some way off."

STFC's Professor Susan Smith, responsible for ALICE, said: "It is fantastic news that, through ALICE, we now have an improved technology that could lead to significant advances in the treatment of cancer. With ALICE we have an opportunity to look at cells in a way that has not been done before. It is particularly exciting that these experiments are now pointing towards an accurate diagnostic test that could change the lives of thousands of patients and we look forward to continuing to work with Professor Weightman as he takes this invaluable research to the next level."

ALICE, at STFC's Daresbury Laboratory in Cheshire, is an R&D prototype for the next generation of particle accelerators and is the first of its kind in Europe. It is based upon a new mode of operation, known as energy recovery, where the energy used to create its high energy beam is captured and re-used after each circuit of the accelerator, so less power is required making it cheaper to run. Electrons are sent round the accelerator at 99.99% of the speed of light and 99.9% of the power at the final accelerator stage is recovered and re-used.

Provided by Science and Technology Facilities Council search and more info website

5 /5 (2 votes)  

Rank 5 /5 (2 votes)
Relevant PhysicsForums posts

More news stories

New fluorescent tools for cancer diagnosis

In recent years, microRNAs (miRNAs) and other non-coding RNAs are small molecules that help control the expression of specific proteins. In recent years they have emerged as disease biomarkers. miRNA profiles have been used ...

Cancer created 14 hours ago | popularity not rated yet | comments 0

Modulating the immune system to combat metastatic cancer

Cancer cells spread and grow by avoiding detection and destruction by the immune system. Stimulation of the immune system can help to eliminate cancer cells; however, there are many factors that cause the immune system to ...

Cancer created 14 hours ago | popularity 5 / 5 (1) | comments 0

Scientists put bowel cancer under the microscope

Researchers from London's Kingston University have begun a two-year study which could help prolong the lives of people with colorectal tumours.

Cancer created 18 hours ago | popularity 5 / 5 (1) | comments 0

Researcher identifies breast cancer fighting hormone

Transformative research from Western University has identified new hormones in the body which may suppress breast cancer and stimulate the regression of breast tumors.

Cancer created 18 hours ago | popularity 5 / 5 (2) | comments 0

Ground breaking cancer research finds immune system link

(Medical Xpress)—Curtin University researchers have found evidence that targeting specific cells in the body can reverse the effects of cancer on the immune system.

Cancer created 19 hours ago | popularity 5 / 5 (4) | comments 0


Engineered cytomegalovirus protects monkeys from HIV equivalent

(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...

Researchers identify first drug targets in childhood genetic tumor disorder

Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...

Hormone levels may provide key to understanding psychological disorders in women

Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.

Going live: Immune cell activation in multiple sclerosis

Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...

Help at hand for people with schizophrenia

How can healthy people who hear voices help schizophrenics? Finding the answer for this is at the centre of research conducted at the University of Bergen.

Alzheimer's disease, the soft target of the euthanasia debate

(Medical Xpress)—The way Alzheimer's disease is portrayed by advocacy groups and the media is having undue influence on the euthanasia debate, according to a Deakin University nursing ethics professor.